The ratio between dendritic cells and T cells determines whether prostaglandin E2 has a stimulatory or inhibitory effect

Cellular Immunology

Volumn 281, Issue 1, 2013, Pages 62-67

  Shimabukuro Vornhagen, Alexander ^a   Liebig, Tanja M ^a   Koslowsky, Thomas ^b   Theurich, Sebastian ^a   von Bergwelt Baildon, Michael S ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b St Elisabeth Hospital   (Germany)

Author keywords

Cancer vaccine; Dendritic cell; IDO; Prostaglandin E2; Tumor induced immunosuppression

Indexed keywords

INDOLEAMINE 2,3 DIOXYGENASE; PROSTAGLANDIN E2;

ANTIGEN PRESENTING CELL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FUNCTION; CELL INTERACTION; CELL MATURATION; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; DENDRITIC CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; T LYMPHOCYTE;

ANTIGEN PRESENTATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CYTOKINES; DENDRITIC CELLS; DINOPROSTONE; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; LYMPHOCYTE COUNT; T-LYMPHOCYTES;

EID: 84874405323     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2013.01.001     Document Type: Article

References (41)

1. Rosenberg S.A., Yang J.C., Restifo N.P. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 2004, 10:909-915.
2. Jonuleit H., Kuhn U., Muller G., Steinbrink K., Paragnik L., Schmitt E., Knop J., Enk A.H. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur. J. Immunol. 1997, 27:3135-3142.
3. Wobser M., Voigt H., Houben R., Eggert A.O., Freiwald M., Kaemmerer U., Kaempgen E., Schrama D., Becker J.C. Dendritic cell based antitumor vaccination: impact of functional indoleamine 2,3-dioxygenase expression. Cancer Immunol. Immunother.: CII 2007, 56:1017-1024.
4. Moller I., Michel K., Frech N., Burger M., Pfeifer D., Frommolt P., Veelken H., Thomas-Kaskel A.K. Dendritic cell maturation with poly(I:C)-based versus PGE2-based cytokine combinations results in differential functional characteristics relevant to clinical application. J. Immunother. 2008, 31:506-519.
5. Harizi H., Juzan M., Pitard V., Moreau J.F., Gualde N. Cyclooxygenase-2-issued prostaglandin e(2) enhances the production of endogenous IL-10, which down-regulates dendritic cell functions. J. Immunol. 2002, 168:2255-2263.
6. Sá-Nunes A., Bafica A., Lucas D.A., Conrads T.P., Veenstra T.D., Andersen J.F., Mather T.N., Ribeiro J.M.C., Francischetti I.M.B. Prostaglandin E2 is a major inhibitor of dendritic cell maturation and function in ixodes scapularis saliva. J. Immunol. 2007, 179:1497-1505. (Baltimore, Md.: 1950).
7. Shiraishi H., Yoshida H., Saeki K., Miura Y., Watanabe S., Ishizaki T., Hashimoto M., Takaesu G., Kobayashi T., Yoshimura A. Prostaglandin E2 is a major soluble factor produced by stromal cells for preventing inflammatory cytokine production from dendritic cells. Int. Immunol. 2008, 20:1219-1229.
8. Harizi H., Grosset C., Gualde N. Prostaglandin E2 modulates dendritic cell function via EP2 and EP4 receptor subtypes. J. Leukoc. Biol. 2003, 73:756-763.
9. Harizi H., Gualde N. Pivotal role of PGE2 and IL-10 in the cross-regulation of dendritic cell-derived inflammatory mediators. Cell Mol. Immunol. 2006, 3:271-277.
10. Jongmans W., Tiemessen D.M., van Vlodrop I.J.H., Mulders P.F.A., Oosterwijk E. Th1-polarizing capacity of clinical-grade dendritic cells is triggered by Ribomunyl but is compromised by PGE2: the importance of maturation cocktails. J. Immunother. 2005, 28:480-487. (Hagerstown, Md.: 1997).
11. Pockaj B.A., Basu G.D., Pathangey L.B., Gray R.J., Hernandez J.L., Gendler S.J., Mukherjee P. Reduced T-cell and dendritic cell function is related to cyclooxygenase-2 overexpression and prostaglandin E2 secretion in patients with breast cancer. Ann. Surg. Oncol. 2004, 11:328-339.
12. Jing H., Vassiliou E., Ganea D. Prostaglandin E2 inhibits production of the inflammatory chemokines CCL3 and CCL4 in dendritic cells. J. Leukoc. Biol. 2003, 74:868-879.
13. Ahmadi M., Emery D.C., Morgan D.J. Prevention of both direct and cross-priming of antitumor CD8+ T-cell responses following overproduction of prostaglandin E2 by tumor cells in vivo. Cancer Res. 2008, 68:7520-7529.
14. Spaggiari G.M., Abdelrazik H., Becchetti F., Moretta L. Mesenchymal stem cells (MSC) inhibit monocyte-derived dendritic cell (DC) maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2. Blood 2009.
15. Kaliński P., Schuitemaker J.H., Hilkens C.M., Kapsenberg M.L. Prostaglandin E2 induces the final maturation of IL-12-deficient CD1a+CD83+ dendritic cells: the levels of IL-12 are determined during the final dendritic cell maturation and are resistant to further modulation. J. Immunol. 1998, 161:2804-2809. (Baltimore, Md.: 1950).
16. von Bergwelt-Baildon M.S., Popov A., Saric T., Chemnitz J., Classen S., Stoffel M.S., Fiore F., Roth U., Beyer M., Debey S., Wickenhauser C., Hanisch F.G., Schultze J.L. CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition. Blood 2006, 108:228-237.
17. Lee S.Y., Choi H.K., Lee K.J., Jung J.Y., Hur G.Y., Jung K.H., Kim J.H., Shin C., Shim J.J., In K.H., Kang K.H., Yoo S.H. The immune tolerance of cancer is mediated by IDO that is inhibited by COX-2 inhibitors through regulatory T cells. J. Immunother. 2009, 32:22-28. (Hagerstown, Md.: 1997).
18. Schmidt L.M., Belvisi M.G., Bode K.A., Bauer J., Schmidt C., Suchy M.T., Tsikas D., Scheuerer J., Lasitschka F., Grone H.J., Dalpke A.H. Bronchial epithelial cell-derived prostaglandin E2 dampens the reactivity of dendritic cells. J. Immunol. 2011, 186:2095-2105.
19. Sombroek C.C., Stam A.G., Masterson A.J., Lougheed S.M., Schakel M.J., Meijer C.J., Pinedo H.M., van den Eertwegh A.J., Scheper R.J., de Gruijl T.D. Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation. J. Immunol. 2002, 168:4333-4343.
20. Greenhough A., Smartt H.J., Moore A.E., Roberts H.R., Williams A.C., Paraskeva C., Kaidi A. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 2009, 30:377-386.
21. Braun D., Longman R.S., Albert M.L. A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic-cell maturation. Blood 2005, 106:2375-2381.
22. Legler D.F., Krause P., Scandella E., Singer E., Groettrup M. Prostaglandin E2 is generally required for human dendritic cell migration and exerts its effect via EP2 and EP4 receptors. J. Immunol. 2006, 176:966-973. (Baltimore, Md.: 1950).
23. Rubio M.T., Means T.K., Chakraverty R., Shaffer J., Fudaba Y., Chittenden M., Luster A.D., Sykes M. Maturation of human monocyte-derived dendritic cells (MoDCs) in the presence of prostaglandin E2 optimizes CD4 and CD8 T cell-mediated responses to protein antigens: role of PGE2 in chemokine and cytokine expression by MoDCs. Int. Immunol. 2005, 17:1561-1572.
24. Krause P., Bruckner M., Uermösi C., Singer E., Groettrup M., Legler D.F. Prostaglandin E(2) enhances T-cell proliferation by inducing the costimulatory molecules OX40L, CD70, and 4-1BBL on dendritic cells. Blood 2009, 113:2451-2460.
25. Krause P., Singer E., Darley P.I., Klebensberger J., Groettrup M., Legler D.F. Prostaglandin E2 is a key factor for monocyte-derived dendritic cell maturation: enhanced T cell stimulatory capacity despite IDO. J. Leukoc. Biol. 2007, 82:1106-1114.
26. Scandella E., Men Y., Gillessen S., Förster R., Groettrup M. Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells. Blood 2002, 100:1354-1361.
27. Simon T., Fonteneau J.F., Gregoire M. Dendritic cell preparation for immunotherapeutic interventions. Immunotherapy 2009, 1:289-302.
28. Palucka K., Ueno H., Roberts L., Fay J., Banchereau J. Dendritic cells: are they clinically relevant?. Cancer J. 2010, 16:318-324.
29. Herfs M., Herman L., Hubert P., Minner F., Arafa M., Roncarati P., Henrotin Y., Boniver J., Delvenne P. High expression of PGE2 enzymatic pathways in cervical (pre)neoplastic lesions and functional consequences for antigen-presenting cells. Cancer Immunol. Immunother. 2009, 58:603-614.
30. Munn D.H., Sharma M.D., Mellor A.L. Ligation of B7-1/B7-2 by human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells. J. Immunol. 2004, 172:4100-4110.
31. Gilboa E. DC-based cancer vaccines. J. Clin. Invest. 2007, 117:1195-1203.
32. Terness P., Chuang J.J., Bauer T., Jiga L., Opelz G. Regulation of human auto- and alloreactive T cells by indoleamine 2,3-dioxygenase (IDO)-producing dendritic cells: too much ado about IDO?. Blood 2005, 105:2480-2486.
33. Munn D.H., Mellor A.L., Rossi M., Young J.W. Dendritic cells have the option to express IDO-mediated suppression or not. Blood 2005, 105:2618.
34. Lob S., Ebner S., Wagner S., Weinreich J., Schafer R., Konigsrainer A. Are indoleamine-2,3-dioxygenase producing human dendritic cells a tool for suppression of allogeneic T-cell responses?. Transplantation 2007, 83:468-473.
35. Muller A.J., Mandik-Nayak L., Prendergast G.C. Beyond immunosuppression: reconsidering indoleamine 2,3-dioxygenase as a pathogenic element of chronic inflammation. Immunotherapy 2010, 2:293-297.
36. Hopken U.E., Lehmann I., Droese J., Lipp M., Schuler T., Rehm A. The ratio between dendritic cells and T cells determines the outcome of their encounter: proliferation versus deletion. Eur. J. Immunol. 2005, 35:2851-2863.
37. Lee J.J., Takei M., Hori S., Inoue Y., Harada Y., Tanosaki R., Kanda Y., Kami M., Makimoto A., Mineishi S., Kawai H., Shimosaka A., Heike Y., Ikarashi Y., Wakasugi H., Takaue Y., Hwang T.J., Kim H.J., Kakizoe T. The role of PGE(2) in the differentiation of dendritic cells: how do dendritic cells influence T-cell polarization and chemokine receptor expression?. Stem Cells 2002, 20:448-459.
38. Lehner M., Stilper A., Morhart P., Holter W. Plasticity of dendritic cell function in response to prostaglandin E2 (PGE2) and interferon-gamma (IFN-gamma). J. Leukoc. Biol. 2008, 83:883-893.
39. Basu G.D., Tinder T.L., Bradley J.M., Tu T., Hattrup C.L., Pockaj B.A., Mukherjee P. Cyclooxygenase-2 inhibitor enhances the efficacy of a breast cancer vaccine: role of IDO. J. Immunol. 2006, 177:2391-2402.
40. Jung I.D., Jeong Y.I., Lee C.M., Noh K.T., Jeong S.K., Chun S.H., Choi O.H., Park W.S., Han J., Shin Y.K., Kim H.W., Yun C.H., Park Y.M. COX-2 and PGE2 signaling is essential for the regulation of IDO expression by curcumin in murine bone marrow-derived dendritic cells. Int. Immunopharmacol. 2010, 10:760-768.
41. Banerjee D.K., Dhodapkar M.V., Matayeva E., Steinman R.M., Dhodapkar K.M. Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients. Blood 2006, 108:2655-2661.